Skip to content

FG-3019 · CTGF / CTGF-N

Fixed rat antibody binding-site disposition, independent intact/fragment target turnover and two explicit antibody-elimination pathways.

FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition ↗
Exploration notes · What are you exploring?

Notes stay on this browser.

MODEL IN MOTION 18 sec

How does FG-3019 dose alter free antibody and intact CTGF in rats?

Run settings

Run location

Explore this model

Choose a scenario, adjust inputs, and run the simulation.

FG-3019 0.03 mg/kg · endogenous equilibrium

Fixed antibody-site bolus with endogenous targets initially at equilibrium.

0–2,996 hour

Scenario details

FG-3019 0.03 mg/kg · endogenous equilibrium

Fixed antibody-site bolus with endogenous targets initially at equilibrium.

Readouts

Antibody total plasma · nmol/L
Total plasma antibody binding-site equivalents, free plus either represented complex.
Intact ctgf total plasma · nmol/L
Intact CTGF plasma signal, free plus antibody-associated.
Nplus w assay plasma · nmol/L
Combined modeled N-fragment plus intact CTGF plasma signal; distinct from intact-specific signal.
Target mediated cumulative fraction · dimensionless
Target-pathway share of the amount eliminated so far; defined as zero before elimination. No infinite-tail or population claim.
Antibody balance defect · nmol
Difference from the complete specified antibody-site bolus input; ligand inputs are separate.

Study purpose

  • How do the model's key biological readouts change under fg-3019 0.03 mg/kg · endogenous equilibrium?

Assumptions

  • Fixed 0.3 kg rat or target-specific assay reference, not a clinical dose prediction.
  • Antibody molar coordinates represent 75 kDa binding-site equivalents.
  • Finite-window pathway integrals do not reconstruct original fitting or NCA.

Inputs changed since the displayed result. Run to update the comparison.

Loading starting example…

Edit inputs

Simulation time
h
h
2996 → 168

Time between reported samples.

h
2996 → 1

2 changes · Variation 1

Continue in the background and keep the result.

Biology

Fixed rat antibody binding-site disposition, independent intact/fragment target turnover and two explicit antibody-elimination pathways.

Fixed rat antibody binding-site disposition, independent intact/fragment target turnover and two explicit antibody-elimination pathways.

Model details

18 parameters · 12 states · 12 equations · 34 derived outputs

Classification & API access
Therapeutic
FG-3019
Modality
Antibody fragment
Target
Connective tissue growth factor (CTGF)
Disease / scope
Rat antibody disposition (not disease-specific)
ParameterDefaultUnitDescription
ClabCLAb0.0001321L/hFixed source coefficient or supplied antibody-input ledger; parameter editing is disabled.
ClwCLW0.09243L/hFixed source coefficient or supplied antibody-input ledger; parameter editing is disabled.
ClwtCLWT1.38L/hFixed source coefficient or supplied antibody-input ledger; parameter editing is disabled.
Cld abCLdAb0.0005692L/hFixed source coefficient or supplied antibody-input ledger; parameter editing is disabled.
Cld ab wCLdAbW10L/hFixed source coefficient or supplied antibody-input ledger; parameter editing is disabled.
Cld nCLdN0.07998L/hFixed source coefficient or supplied antibody-input ledger; parameter editing is disabled.
Cld wCLdW10L/hFixed source coefficient or supplied antibody-input ledger; parameter editing is disabled.
CN0CN00.6572nmol/LFixed source coefficient or supplied antibody-input ledger; parameter editing is disabled.
CW0CW00.02591nmol/LFixed source coefficient or supplied antibody-input ledger; parameter editing is disabled.
KdnKDN51.21nmol/LFixed source coefficient or supplied antibody-input ledger; parameter editing is disabled.
KdwKDW23.97nmol/LFixed source coefficient or supplied antibody-input ledger; parameter editing is disabled.
Apparent distribution volumeV0.01512LFixed source coefficient or supplied antibody-input ledger; parameter editing is disabled.
Vab tVAbT0.01363LFixed source coefficient or supplied antibody-input ledger; parameter editing is disabled.
VntVNT0.04458LFixed source coefficient or supplied antibody-input ledger; parameter editing is disabled.
VwtVWT0.116LFixed source coefficient or supplied antibody-input ledger; parameter editing is disabled.
Administered ab nmolsadministered_Ab_nmols0nmolFixed source coefficient or supplied antibody-input ledger; parameter editing is disabled.
Dissociation rate nkoffN1001/hFixed source coefficient or supplied antibody-input ledger; parameter editing is disabled.
Dissociation rate wkoffW1001/hFixed source coefficient or supplied antibody-input ledger; parameter editing is disabled.

Related models

Feedback: helpdesk@unibiointelligence.com.

Ubi Biologics